Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2017

Oct 3, 2017

29977_dirs_2017-10-03_f0305fe6-32e5-4d11-aac0-f35734cd1d25.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-09-29

Reporting Person: BAKER CHARLES A (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-09-29 Common Stock M 2000 $18.61 Acquired 11000 Direct
2017-09-29 Common Stock S 2000 $450.0 Disposed 9000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-09-29 Non-Qualified Stock Option (right to buy) $18.61 M 2000 Disposed 2019-01-02 Common Stock (2000) Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.